RxDoctor Payments Data

Ashley Ferraro, DO

Pulmonary Disease · Shreveport, LANPI 1912917139

Payments from drug & device makers

$10,245in general payments, 2019–2025

Across 29 payments — averaging $353.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$9K
  • Noah Medical Corporation$638
  • Insmed, Inc.$115
  • Actelion Pharmaceuticals US, Inc.$65
  • GSK$34
  • Veran Medical Technologies, Inc.$31
  • plus $101 from 6 others

What the payments were for

  • Travel & lodging$5856%
  • Food & beverage$1,16011%
  • Education$8,50083%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,245 in reported general payments places this provider in the 65th percentile of 189 pulmonary disease providers in Louisiana.

See all pulmonary disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$89,751
Medicare patients
261
Services billed
896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Spiriva RespimatTiotropium Bromide17$12,711
SymbicortBudesonide/Formoterol Fumarate29$12,319
Combivent RespimatIpratropium/Albuterol Sulfate21$11,809
Breo ElliptaFluticasone/Vilanterol27$10,025
Spiriva HandihalerTiotropium Bromide15$9,698
Incruse ElliptaUmeclidinium Bromide14$7,130
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$4,983
Fluticasone Propionate HfaFluticasone Propionate14$2,813
Albuterol Sulfate HfaAlbuterol Sulfate72$2,344
Ventolin HfaAlbuterol Sulfate15$1,214
Roflumilast12$632
Montelukast Sodium29$478
Methylprednisolone25$335
Fluticasone Propionate11$194
Prednisone27$102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSpiriva Respimat, Combivent Respimat$20$24,52138 claims
GSKBreo Ellipta, Incruse Ellipta, Anoro Ellipta$34$22,13752 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 189 pulmonary disease providers in Louisiana.

Other pulmonary disease in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →